MedTrace Logo

Ranibizumab Versus PDT for Presumed Ocular Histoplasmosis

NCT00546936 · Status: UNKNOWN · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 30

Last updated 2009-04-16

No results posted yet for this study

Summary

The purpose of this study is to evaluate the change in visual activity of ranibizumab to Photodynamic Therapy (PDT)in patients with choroidal neovascularization (CNV) secondary to presumed ocular histoplasmosis

Conditions

  • Presumed Ocular Histoplasmosis (POHS)

Interventions

DRUG

ranibizumab

0.5mg ranibizumab

DRUG

verteporfin

Photodynamic therapy with verteporfin every 3 months for 1 year

Sponsors & Collaborators

  • Genentech, Inc.

    collaborator INDUSTRY

  • Barnes Retina Institute

    lead OTHER

Principal Investigators

  • Kevin J. Blinder, MD · Barnes Retina Institute

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
21 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2007-10-31
Primary Completion
2009-10-31
Completion
2010-04-30

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT00546936 on ClinicalTrials.gov